DPHARMA

Quarterly rpt on consolidated results for the financial period ended 30 Jun 2018

Amended Announcements
Please refer to the earlier announcement reference number: FRA-24082018-00066

CCM DUOPHARMA BIOTECH BERHAD

Financial Year End 31 Dec 2018
Quarter 2 Qtr
Quarterly report for the financial period ended 30 Jun 2018
The figures have not been audited

Attachments

CCMDBIO-Q2 2018 - amended 14112018 (marked).xls
139.0 kB


Remarks : 
Amendments have been made to columns 1 to 4 of item no. 5, columns 2 and 4 of item no. 6 and columns 1 and 2 of item no. 7 of Part A2: Summary of Key Financial Information in respect of the Basic earnings/(loss) per share (Subunit), Proposed/ Declared Dividend per share and Net Assets per share attributable to ordinary equity holders of the parent. An amendment has also been made in respect of Note B11(a) and (b) in relation to the Basic EPS and the Dilutive EPS respectively, on pages 4 and 5 of the Notes to Interim Financial Report for the Quarterly Report on Results for the Financial Year Ended 30 June 2018, as attached.

As announced by the Company on 20 June 2018, the bonus issue by the Company had been completed following the listing of and quotation for 371,943,071 new bonus shares on the Main Market of Bursa Malaysia Securities Berhad on 20 June 2018.  The calculations of the Basic EPS (sen), Dilutive EPS (sen), Proposed/ Declared dividend per share and Net Assets per share attributable to ordinary equity holders of the parent have been amended to take into account of the effect of the bonus issue.
  • Default Currency
  • Other Currency

Currency: Malaysian Ringgit (MYR)

SUMMARY OF KEY FINANCIAL INFORMATION
30 Jun 2018

 
INDIVIDUAL PERIOD
CUMULATIVE PERIOD
CURRENT YEAR QUARTER
PRECEDING YEAR
CORRESPONDING
QUARTER
CURRENT YEAR TO DATE
PRECEDING YEAR
CORRESPONDING
PERIOD
30 Jun 2018
30 Jun 2017
30 Jun 2018
30 Jun 2017
$$'000
$$'000
$$'000
$$'000
1 Revenue
123,991
117,049
257,250
240,355
2 Profit/(loss) before tax
12,915
12,642
26,170
24,764
3 Profit/(loss) for the period
10,339
9,641
20,986
19,205
4 Profit/(loss) attributable to ordinary equity holders of the parent
10,339
9,653
20,986
19,217
5 Basic earnings/(loss) per share (Subunit)
1.59
1.48
3.22
2.95
6 Proposed/Declared dividend per share (Subunit)
1.50
1.07
1.50
1.07


AS AT END OF CURRENT QUARTER
AS AT PRECEDING FINANCIAL YEAR END
7
 Net assets per share attributable to ordinary equity holders of the parent ($$)
0.7500
0.7400

Definition of Subunit:

In a currency system, there is usually a main unit (base) and subunit that is a fraction amount of the main unit.
Example for the subunit as follows:

Country Base Unit Subunit
Malaysia Ringgit Sen
United States Dollar Cent
United Kingdom Pound Pence



Announcement Info

Company Name CCM DUOPHARMA BIOTECH BERHAD
Stock Name CCMDBIO
Date Announced 26 Nov 2018
Category Financial Results
Reference Number FRA-26112018-00024


View original report